In July 2020, NICE published two new Interventional Procedure Guidance: Artificial iris insertion for acquired aniridia and Artificial iris insertion for congenital aniridia.
Interventional Procedure Guidance is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from ‘for research only’ to ‘for use with standard arrangements for clinical governance, consent, and audit.' Recommendations are not binding, although they are followed by providers and commissioners.
Evidence on the safety and efficacy of artificial iris implant insertion for acquired aniridia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.
Evidence on the safety and efficacy of artificial iris implant insertion for congenital aniridia is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.
MedTech Innovation Briefing is the NICE's advice program for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations.
Two new Medtech Innovation Briefings for Prontosan for acute and chronic wounds (to cleanse acute and chronic wounds) and CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (a digital platform to help adults with cystic fibrosis (CF) manage their condition and monitor their medicine use) have been published in July.
See the full details here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.